Pathovacs, INC. Will develop a prototype in vitro diagnostic device for qualitative screening of individuals for anti-hepatitis C virus (HCV) antibodies to determine HCV exposure.
Ended Definitive Contract Awarded Last action
- Contract number
- 75N91022C00027
- Awardee
-
Pathovacs Inc. UEI GAEYBFGAB1N9
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $393,833
Award facts
- Opportunity
-
- A Solicitation of the National Institutes of Health (NIH) and The Centers for Disease Control and Prevention (CDC) for Small Business Innovation Research (SBIR) Contract Proprosals Pre-Solicitation · PHS20211 · Posted Jul 9, 2020
- Contract value 100% obligated
- $393,833.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 15 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Ames, IA 50011, USA
- Research
- SBIR Program Phase I Action
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Original award | $393,833 |
About this award
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), which is part of the National Institutes of Health (NIH), to Pathovacs Inc., a small biotechnology company based in Ames, Iowa. The $393,833 firm-fixed-price contract supports the development of a prototype in vitro diagnostic device for qualitative screening of individuals for anti-hepatitis C virus (HCV) antibodies to determine HCV exposure. This aligns with the NCI's mission to advance cancer and infectious disease research. The contract was set aside for small businesses and will run through September 2023, with the goal of delivering a simple at-home test for rapid and accurate screening for HCV exposure.
Quick answers
Who was awarded contract 75N91022C00027?
75N91022C00027 was awarded to Pathovacs Inc. by National Cancer Institute (National Institutes of Health) on September 20, 2022.
How much is contract 75N91022C00027 worth?
The government has obligated $393,833 on 75N91022C00027.
Was contract 75N91022C00027 competed?
The extent of competition for 75N91022C00027 was full and open competition after exclusion of sources. The government received 15 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award